ArticleOncoimmunology2013
Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.British journal of cancer · 2015Trial
- Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.International journal of molecular sciences · 2014Trial
- Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.Oncoimmunology · 2022Article
- Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Article
- Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle.Journal of gastrointestinal oncology · 2018Review
- Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling.Frontiers in immunology · 2018Article
- Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Apigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer.PloS one · 2017Article
- Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2015Article
- Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.Oncoimmunology · 2015Article
- Murine pancreatic adenocarcinoma reduces Ikaros expression and disrupts T cell homeostasis.PloS one · 2015Article
- The complex landscape of pancreatic cancer metabolism.Carcinogenesis · 2014Review
- Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.Cancer immunology, immunotherapy : CII · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of malignancy. Via a broad stimulation of the immune system, PDAC activates both antitumor immune responses and immunosuppressive mechanisms. We propose that new immunotherapeutic strategies for the management of PDAC should be designed to specifically neutralize the immunosuppressive tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.